GlassScriptPhysician profile
George J Wang
NPI 1205005584
$3,747.90
in general payments reported to CMS, 2019-2025
33 companies · $1,392 in 2025
The $1,392 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $459 · 2021: $204 · 2022: $91.28 · 2023: $289 · 2024: $882 · 2025: $1,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,563.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $680.82 | 2023-2024 | Affinity, Cygnus Dual, Puraply |
| Smith+Nephew, INC. | $634.44 | 2019-2025 | Collagenase Santyl, Grafix, Grafix Pl |
| Abbvie INC. | $502.28 | 2021-2025 | Avycaz |
| Strata Skin Sciences, INC. | $200.62 | 2024-2025 | Xtrac |
| Kci USA, INC. | $195.03 | 2020-2023 | Activ.A.C., V.A.C. Dermatac |
| Allergan, INC. | $171.41 | 2019-2020 | |
| Galderma Laboratories, L.P. | $157.60 | 2025 | Nemluvio |
| Genzyme Corporation | $137.63 | 2025 | |
| Melinta Therapeutics, LLC | $96.21 | 2019 | |
| Organon LLC | $96.07 | 2025 | Vtama |
| Lilly USA, LLC | $95.62 | 2024-2025 | Taltz, Ebglyss, Zepbound |
| Tactile Systems Technology INC | $81.60 | 2020-2023 | Entre Plus, Flexitouch Plus |
| Biofrontera INC. | $65.29 | 2025 | |
| Ucb, INC. | $63.85 | 2025 | Bimzelx |
| Abbott Laboratories | $61.66 | 2025 | Id Now Instrument |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $52.03 | 2020-2021 | |
| Novo Nordisk INC | $47.11 | 2020 | |
| Hartmann USA, INC. | $45.74 | 2020 | |
| Amgen INC. | $43.87 | 2024-2025 | Otezla, Otezla |
| Revance Therapeutics, INC. | $40.62 | 2025 | Daxxify |
| Paratek Pharmaceuticals, INC. | $37.88 | 2020-2025 | Nuzyra |
| Pfizer INC. | $28.42 | 2020 | |
| Janssen Biotech, INC. | $26.70 | 2024 | Tremfya |
| Leo Pharma INC. | $24.72 | 2025 | Anzupgo |
| Medela LLC | $23.49 | 2020 | |
| Lnhc, INC | $20.79 | 2025 | Zelsuvmi |
| Verrica Pharmaceuticals INC. | $20.79 | 2024 | Ycanth |
| Lundbeck LLC | $18.57 | 2024 | Rexulti |
| Convatec INC. | $17.16 | 2020 | |
| Sun Pharmaceutical Industries INC. | $16.42 | 2025 | |
| Zimmer Biomet Holdings, INC. | $15.67 | 2025 | Gel-One Cross-Linked Hyaluronate |
| E.R. Squibb & Sons, L.L.C. | $14.99 | 2020 | |
| Acera Surgical, INC. | $12.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.